Pharma channel feed – Endpoints News

Pharma channel feed

After talking to Trump about top FDA job, Balaji Srinivasan erased his barbed criticism of the drug agency

9 years ago

Is Spinraza worth $750K? Biogen says yes, spelling out reduced death risk

9 years ago

Failed Nivalis pares down to a skeleton crew as it launches a salvage operation

9 years ago

As Trump fingers pharma on drug prices, execs step up with the latest vows of self discipline

9 years ago

FDA rejects Tesaro’s IV version of rolapitant, citing manufacturing issues

9 years ago

Donald Trump promises to slash drug prices by billions, pledging aggressive federal bidding process

9 years ago

Daiichi Sankyo launches global R&D restructuring, looking to slash costs in an overhaul

9 years ago

In a stunner, Merck leaps ahead of rivals with combo Keytruda/chemo attack on lung cancer

9 years ago

Merck KGaA splurges $230M on its pipeline, paying Vertex for a slate of early-stage cancer drugs

9 years ago

A hungry Takeda continues deal spree with $125M T cell pact, option to buy

9 years ago

Struggling Sarepta bounces back as analysts cheer the first trickle of revenue for DMD drug

9 years ago

J&J Innovation expands its biotech incubator JLABS into Manhattan

9 years ago

Fresh from grabbing Shire’s mRNA work, RaNA discloses a $51M raise

9 years ago

Kite lines up a JV in China while Daiichi Sankyo strikes $250M-plus deal to launch CAR-T drug in Japan

9 years ago

Allergan bags two new deals, takes option to buy Lysosomal Therapeutics and pays $50M for microbiome pact

9 years ago

Novartis adds to its cardio pipeline with $1.65B Ionis pact

9 years ago

Analysts assess the damage — and next steps — after Regeneron/Sanofi get slammed in court

9 years ago

J&J grabs an option to buy a NASH drug in latest string of biotech deals

9 years ago

M&A inflation just pushed the average biopharma valuation to a scary new peak

9 years ago

New drug price controversy looms as Biogen stuns payers with Spinraza's $750K sticker — analyst

9 years ago

Biogen, Ionis win FDA OK for spinal muscular atrophy drug Spinraza

9 years ago

WSJ's editorial page puts the blame over Exondys 51 controversy on insurers, regulators and reporters

9 years ago

ChemoCentryx grabs $50M upfront, adds development partnership with Vifor

9 years ago

The Senate dissects Martin Shkreli's scheme to grab a $1B windfall

9 years ago

First page Previous page 335 336 337338339 340 341 Next page Last page